Fluorescent Polyelectrolyte System to Track Anthocyanins Delivery inside Melanoma Cells.

Over the past decades, there has been a growing interest in using natural molecules with therapeutic potential for biomedical applications. In this context, our aim is focused on anthocyanins (AN) as molecules with anticancer properties that could be used in melanoma local therapies. Due to their susceptibility to environmental changes, current study is based on the design and development of a fluorescent system for carrying and trafficking AN inside melanoma cells. The architectural structure of the proposed system CaCO3(PAH)@RBITC@AN reflects a spherical shape, 1080 nm diameter and a solid groundwork CaCO3(PAH), on which rhodamine B isothiocyanate (RBITC) fluorophore was firstly added; then, poly(acrylic acid) (PAA) polyelectrolytes and poly(allylamine hydrochloride) (PAH) were successfully deposited. Purified AN from chokeberries were entrapped between PAA layers (rate of 94.6%). In vitro tests confirmed that CaCO3(PAH)@RBITC@AN does not affect the proliferation of melanoma B16-F10 cells and proved that their internalization and trafficking can be followed after 24 h of treatment. Data presented here could contribute not only to the existing knowledge about the encapsulation technology of AN but also might bring relevant information for a novel formula to deliver therapeutic molecules or other bio-imaging agents directly into melanoma cells, a strategy that could positively improve tumor therapies.

Resveratrol-delivery vehicle with anti-VEGF activity carried to human retinal pigmented epithelial cells exposed to high-glucose induced conditions.

As an integrated approach to defeat diabetic retinopathy, a common complication of diabetes leading to vision loss, a delivery vehicle able to transport resveratrol (Rv) directly into retina pigmented epithelial D407 cells was designed. Rv, a molecule with known therapeutic potential, was successfully inserted into a microcapsule based on porous CaCO3 templates revealing an encapsulation efficiency of 96.8 ±â€¯4.0%. Four alternative layers of polyelectrolytes were deposited via electrostatic-driven layer-by-layer assembly approach on the template and covered by rhodamine 6G (Rh6G). The as-designed PMs-Rv-Rh6G microcapsules were internalized into D407 cells grown in normal and high glucose-induced inflammation conditions, being able to cross the cellular membrane and localize near the nucleus after 24 h treatment. The metabolic activity of D407 cells was not diminished by PMs-Rv-Rh6G even after 24 h treatment, meaning that the microcapsules do not exert any toxicity toward the cells, based on WST-1 and lactate dehydrogenase assays. Notably, the PMs-Rv-Rh6G treatment is able to inhibit the vascular endothelial growth factor (VEGF) protein, as was proved by the ELISA assay. Therefore, the proposed PMs-Rv-Rh6G microcapsules could be implemented as a potential self-reporting intraocular Rv-delivery vehicle with anti-VEGF activity in the management of diabetic retinopathy.

Novel Strategies for the Improvement of Stem Cells' Transplantation in Degenerative Retinal Diseases.

Currently, there is no cure for the permanent vision loss caused by degenerative retinal diseases. One of the novel therapeutic strategies aims at the development of stem cells (SCs) based neuroprotective and regenerative medicine. The main sources of SCs for the treatment of retinal diseases are the embryo, the bone marrow, the region of neuronal genesis, and the eye. The success of transplantation depends on the origin of cells, the route of administration, the local microenvironment, and the proper combinative formula of growth factors. The feasibility of SCs based therapies for degenerative retinal diseases was proved in the preclinical setting. However, their translation into the clinical realm is limited by various factors: the immunogenicity of the cells, the stability of the cell phenotype, the predilection of SCs to form tumors in situ, the abnormality of the microenvironment, and the association of a synaptic rewiring. To improve SCs based therapies, nanotechnology offers a smart delivery system for biomolecules, such as growth factors for SCs implantation and differentiation into retinal progenitors. This review explores the main advances in the field of retinal transplantology and applications of nanotechnology in the treatment of retinal diseases, discusses the challenges, and suggests new therapeutic approaches in retinal transplantation.